SCHEMBL96008

SCHEMBL96008

[CH2]c1ccc(NS(=O)(=O)c2cc(C)c(Cl)cc2Cl)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.51
HSD17B1 P14061 1/20 0.50
HSD17B2 P37059 1/20 0.50
PGR P06401 1/20 0.49
LMNA P02545 1/20 0.48
ALDH1A1 P00352 2/20 0.48
GAA P10253 1/20 0.48
GFER P55789 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
IDH1 O75874 3/20 0.47
POLB P06746 1/20 0.47
HSD17B10 Q99714 1/20 0.47
CDK1 P06493 2/20 0.47
CCNB1 P14635 2/20 0.47
CCNA2 P20248 2/20 0.47
CDK2 P24941 2/20 0.47
CDK7 P50613 2/20 0.47
CCNH P51946 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14018752 0.82 ALDH1A1 (0.68) L3MBTL1HSD17B1HSD17B2PGRLMNA
SCHEMBL3273156 0.80 L3MBTL1 (0.55) L3MBTL1HSD17B1HSD17B2LMNAALDH1A1
SCHEMBL95688 0.79 PKM (0.60) PGRLMNAALDH1A1MEN1KMT2A
SCHEMBL94976 0.79 MAPT (0.54) PGRLMNAALDH1A1SMN1; SMN2MEN1
SCHEMBL94831 0.78 MAPT (0.63) LMNAALDH1A1MEN1KMT2ACDK1
SCHEMBL95927 0.78 ALDH1A1 (0.67) L3MBTL1LMNAALDH1A1SMN1; SMN2MEN1
SCHEMBL12584959 0.78 POLB (0.62) PGRLMNAALDH1A1GAASMN1; SMN2
SCHEMBL95834 0.76 BRD4 (0.51) HSD17B2LMNASMN1; SMN2MEN1KMT2A
SCHEMBL3268117 0.76 L3MBTL1 (0.51) L3MBTL1HSD17B1HSD17B2PGRLMNA
SCHEMBL95032 0.76 HSD11B1 (0.59) PGRALDH1A1PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8362252-B2 Carbostyril compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-01-29 US disclosed
EP-1797082-B1 CARBOSTYRIL COMPOUND OTSUKA PHARMA CO LTD (JP) 2012-08-29 EP disclosed
EP-2426128-A1 Carbostyril compound Otsuka Pharmaceutical Co., Limited (JP) 2012-03-07 EP disclosed
US-20100261705-A1 CARBOSTYRIL COMPOUND OTSUKA PHARMACEUTICAL CO., LTD. 2010-10-14 US disclosed
US-7777038-B2 Carbostyril compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2010-08-17 US disclosed
US-20090326008-A1 NF-kappa B Inhibitor OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2009-12-31 US disclosed
CN-101489555-A Nf-kappa OTSUKA PHARMA CO LTD (JP) 2009-07-22 CN disclosed
EP-2043644-A1 NF- B INHIBITOR Otsuka Pharmaceutical Co., Ltd. (JP) 2009-04-08 EP disclosed
WO-2008010601-A1 NF- ϰB INHIBITOR OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2008-01-24 WO disclosed
US-20070179173-A1 Carbostyril compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-02 US disclosed
EP-1797082-A1 CARBOSTYRIL COMPOUND Otsuka Pharmaceutical Company, Limited (JP) 2007-06-20 EP disclosed
WO-2006035954-A1 CARBOSTYRIL COMPOUND OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-04-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090326008-A1 NF-kappa B Inhibitor NFKBIA, NFKB2, IKBKB L3MBTL1 1099/4885HSD17B1 577/4885HSD17B2 945/4885
US-20070179173-A1 Carbostyril compound GTF2F1, F3, GTF2F2 L3MBTL1 262/4885HSD17B1 1375/4885HSD17B2 1421/4885
US-20100261705-A1 CARBOSTYRIL COMPOUND GTF2F1, F3, GTF2F2 L3MBTL1 262/4885HSD17B1 1375/4885HSD17B2 1421/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.